Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm

Am J Hematol. 2022 Feb 1;97(2):E62-E67. doi: 10.1002/ajh.26417. Epub 2021 Nov 29.

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
² Department of Leukemia, MD Anderson Cancer Center, Houston, Texas, USA.
³ Division of Hematology, Mayo Clinic, Jacksonville, Florida, USA.
⁴ Division of Hematology, Mayo Clinic, Scottsdale, Arizona, USA.
⁵ Division of Hematopathology, Mayo Clinic, Rochester, Minnesota, USA.

PMID: 34807470
DOI: 10.1002/ajh.26417

No abstract available

Publication types

Letter

MeSH terms

Age Factors
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Dendritic Cells / drug effects
Dendritic Cells / pathology
Female
Hematologic Neoplasms / drug therapy*
Hematologic Neoplasms / epidemiology
Hematologic Neoplasms / pathology
Humans
Male
Middle Aged
Sulfonamides / therapeutic use*

Substances

Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
venetoclax